Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016

  • ID: 3734778
  • Drug Pipelines
  • 94 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Athersys, Inc.
  • BioLineRx, Ltd.
  • Cell2B S.A.
  • FibroGen, Inc.
  • Novartis AG
  • P2D Bioscience
  • MORE
Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016

Summary

‘Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2016’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
- The report reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hematopoietic Stem Cell Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Hematopoietic Stem Cell Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athersys, Inc.
  • BioLineRx, Ltd.
  • Cell2B S.A.
  • FibroGen, Inc.
  • Novartis AG
  • P2D Bioscience
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hematopoietic Stem Cell Transplantation Overview

Therapeutics Development

Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview

Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies

Hematopoietic Stem Cell Transplantation - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Hematopoietic Stem Cell Transplantation - Products under Development by Companies

Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development

Actinium Pharmaceuticals, Inc.

Athersys, Inc.

BioLineRx, Ltd.

Cell2B S.A.

Celldex Therapeutics, Inc.

FibroGen, Inc.

Novartis AG

P2D Bioscience

Polyphor Ltd.

TaiGen Biotechnology Co., Ltd.

Targazyme, Inc.

TikoMed AB

Hematopoietic Stem Cell Transplantation - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Actimab-B - Drug Profile

Product Description

Mechanism of Action

R&D Progress

balixafortide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BL-8040 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

burixafor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Casin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CDX-301 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CordSafe - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FG-6874 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HSC-835 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IBsolvMIR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Iomab-B - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-05285401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

POL-5551 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TZ-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Hematopoietic Stem Cell Transplantation - Recent Pipeline Updates

Hematopoietic Stem Cell Transplantation - Dormant Projects

Hematopoietic Stem Cell Transplantation - Discontinued Products

Hematopoietic Stem Cell Transplantation - Product Development Milestones

Featured News & Press Releases

Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B

Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

Mar 23, 2016: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment

Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B

Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting

Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization

Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015

Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme’s Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie

Mar 18, 2015: TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany

Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by BioLineRx, Ltd., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by FibroGen, Inc., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Polyphor Ltd., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H1 2016

Hematopoietic Stem Cell Transplantation - Pipeline by TikoMed AB, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Hematopoietic Stem Cell Transplantation Therapeutics - Recent Pipeline Updates, H1 2016

Hematopoietic Stem Cell Transplantation - Dormant Projects, H1 2016

Hematopoietic Stem Cell Transplantation - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Hematopoietic Stem Cell Transplantation, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Actinium Pharmaceuticals, Inc.
Athersys, Inc.
BioLineRx, Ltd.
Cell2B S.A.
Celldex Therapeutics, Inc.
FibroGen, Inc.
Novartis AG
P2D Bioscience
Polyphor Ltd.
TaiGen Biotechnology Co., Ltd.
Targazyme, Inc.
TikoMed AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll